New York, May 26, 2026, 15:03 EDT
- NeuroSense shares traded up at $0.87 Tuesday. The stock remains under Nasdaq’s $1 minimum bid-price limit.
- The next things to track for the company are Nasdaq compliance, the Health Canada meeting, and how the PrimeC trial moves ahead.
- NeuroSense is still a clinical-stage biotech with high risk. The company has little cash and needs more funding.
NeuroSense Therapeutics Ltd. (NRSN) added 5 cents to 87 cents during Tuesday’s session as shares edged higher. That kept the ALS biotech under a key Nasdaq price threshold, but closer. Volume was about 78,500 shares. NeuroSense’s market cap was around $15.7 million, as the stock moved between 84 and 87 cents.
NeuroSense is under pressure after warnings from Nasdaq about two key listing standards — the $1 minimum bid price and a $35 million market value of listed securities, or MVLS. Nasdaq uses MVLS to track the value of securities on its exchange. NeuroSense has until Sept. 29, 2026, to fix both issues. The company needs its shares to close at or above $1 for at least 10 days in a row, and its MVLS has to hit $35 million or higher for at least 10 business days, all subject to Nasdaq’s call.
No clear fresh catalyst showed up. NeuroSense’s investor-relations site still pointed to an April 28 press release about an insider-led PIPE deal—private shares directly sold to select investors.
NeuroSense took in $600,000 before expenses by selling 750,000 ordinary shares at 80 cents each, according to an SEC filing. CEO Alon Ben-Noon, CFO Or Eisenberg and a major existing investor each put in $200,000. NeuroSense said it plans to use the money for general corporate needs as it gets closer to clinical and regulatory targets.
Biotech names were higher with the SPDR S&P Biotech ETF up $1.40 at $133.06 in Tuesday’s session. U.S. trading resumed after the Memorial Day break. Nasdaq reported its regular 9:30 a.m. to 4 p.m. ET stock-market hours and listed May 25, Memorial Day, as a holiday.
NeuroSense is working to move PrimeC, an oral drug candidate, forward in ALS. ALS is a fast-moving and fatal condition that harms nerve cells that manage muscle control. PrimeC is a fixed-dose pill that combines ciprofloxacin and celecoxib. The company says the therapy is aimed at several pathways linked to ALS progression.
NeuroSense said in March that PrimeC is now a late-stage clinical asset in 2025, backed by an FDA-cleared Phase 3 program for ALS. CEO Ben-Noon called it “a clear regulatory path forward.” The company also mentioned upcoming talks with Health Canada and said it is getting ready for the PARAGON Phase 3 trial. Phase 3 is typically the large, final study to test a drug’s safety and efficacy. PR Newswire
PARADIGM’s clinical results are still under review. Mass General Brigham said its 68-person Phase 2b trial showed PrimeC was safe and well tolerated. The group reported signals of benefit—people on PrimeC from the start had better function at 18 months and were 64% less likely to face ALS complications like hospital stays, respiratory failure, or death. “The improved functional and biomarker signals we observed support a phase 3 study,” said Merit Cudkowicz, who led the study. Mass General Brigham
The competitive field is not crowded, but it’s not clear. Biogen’s Qalsody, or tofersen, picked up FDA accelerated approval for SOD1-ALS, a genetic subset. Amylyx said in 2024 it began pulling Relyvrio/Albrioza from the U.S. and Canadian markets after the Phase 3 PHOENIX trial. That has investors watching to see if newer ALS drugs can make it through larger confirmatory studies.
NeuroSense’s balance sheet continues to weigh. The company ended 2025 with about $0.2 million in cash, a net loss of $11.1 million for the year, and a shareholders’ deficit at $1.6 million. The April PIPE deal brings in more cash, though it’s limited for late-stage trial plans.
The catch is big: data from the small Phase 2b trial might not be repeated in a larger Phase 3, regulators could turn down or delay the application, and more equity raises could hit current shareholders. NeuroSense’s 2025 annual report flagged Nasdaq listing issues, a going-concern warning, large financing needs, and a risk that its clinical studies may not show safety and efficacy.
NeuroSense shares are up today but still trade below $1. The focus now is on whether the company can hit clinical and funding milestones soon. The market has under four months left to see if that’s enough for NeuroSense to stay on Nasdaq.
